Evidence map›Paper›PMID 28364280›Full record

ArticleProtein & cell2017

Oncogenic miR-19a and miR-19b co-regulate tumor suppressor MTUS1 to promote cell proliferation and migration in lung cancer.

Yuanyuan Gu, Shuoxin Liu, Xiaodan Zhang, Guimin Chen, Hongwei Liang, Mengchao Yu, Zhicong Liao, Yong Zhou, Chen-Yu Zhang, Tao Wang and 3 more

Erratum issuedOpen access · diamondAbstract read
In one paragraph

Article in Protein & cell, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 40 papers.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 62 citations in OpenAlex.

  1. Article
  2. Article
  3. Association of miRNA-17-92 Cluster with Muscle Invasion in Bladder Cancer.International journal of molecular sciences · 2025
    Article
  4. Regulatory Effects ofFood science & nutrition · 2025
    Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Yuanyuan GuState Key Laboratory of Pharmaceutical Biotechnology, Jiangsu Engineering Research Center for Micro, RNA Biology and Biotechnology, NJU Advanced Institute for Life Sciences (NAILS), School of Life Sciences, Nanjing University, Nanjing, 210046, China.
Shuoxin LiuThe Second Department of Medical Oncology, Linyi Tumor Hospital, Linyi, 276000, China.
Xiaodan ZhangState Key Laboratory of Pharmaceutical Biotechnology, Jiangsu Engineering Research Center for Micro, RNA Biology and Biotechnology, NJU Advanced Institute for Life Sciences (NAILS), School of Life Sciences, Nanjing University, Nanjing, 210046, China.
Guimin ChenThe Second Department of Medical Oncology, Linyi Tumor Hospital, Linyi, 276000, China.
Hongwei LiangState Key Laboratory of Pharmaceutical Biotechnology, Jiangsu Engineering Research Center for Micro, RNA Biology and Biotechnology, NJU Advanced Institute for Life Sciences (NAILS), School of Life Sciences, Nanjing University, Nanjing, 210046, China.
Mengchao YuState Key Laboratory of Pharmaceutical Biotechnology, Jiangsu Engineering Research Center for Micro, RNA Biology and Biotechnology, NJU Advanced Institute for Life Sciences (NAILS), School of Life Sciences, Nanjing University, Nanjing, 210046, China.
Zhicong LiaoDepartment of Cardio-Thoracic Surgery, Nanjing Drum Tower Hospital Affiliated to Medical School of Nanjing University and Nanjing Multi-Center Biobank, Nanjing, 210008, China.
Yong ZhouDepartment of Cardio-Thoracic Surgery, Nanjing Drum Tower Hospital Affiliated to Medical School of Nanjing University and Nanjing Multi-Center Biobank, Nanjing, 210008, China.
Chen-Yu ZhangState Key Laboratory of Pharmaceutical Biotechnology, Jiangsu Engineering Research Center for Micro, RNA Biology and Biotechnology, NJU Advanced Institute for Life Sciences (NAILS), School of Life Sciences, Nanjing University, Nanjing, 210046, China.
Tao WangState Key Laboratory of Pharmaceutical Biotechnology, Jiangsu Engineering Research Center for Micro, RNA Biology and Biotechnology, NJU Advanced Institute for Life Sciences (NAILS), School of Life Sciences, Nanjing University, Nanjing, 210046, China. wangtao_pumc@live.cn.
Chen WangState Key Laboratory of Pharmaceutical Biotechnology, Jiangsu Engineering Research Center for Micro, RNA Biology and Biotechnology, NJU Advanced Institute for Life Sciences (NAILS), School of Life Sciences, Nanjing University, Nanjing, 210046, China. chenwang@nju.edu.cn.
Junfeng ZhangState Key Laboratory of Pharmaceutical Biotechnology, Jiangsu Engineering Research Center for Micro, RNA Biology and Biotechnology, NJU Advanced Institute for Life Sciences (NAILS), School of Life Sciences, Nanjing University, Nanjing, 210046, China. jfzhang@nju.edu.cn.
Xi ChenState Key Laboratory of Pharmaceutical Biotechnology, Jiangsu Engineering Research Center for Micro, RNA Biology and Biotechnology, NJU Advanced Institute for Life Sciences (NAILS), School of Life Sciences, Nanjing University, Nanjing, 210046, China. xichen@nju.edu.cn.
Nanjing University · CNLinyi People's Hospital · CNNanjing Drum Tower Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

MTUS1 (microtubule-associated tumor suppressor 1) has been identified that can function as a tumor suppressor gene in many malignant tumors. However, the function and mechanisms underlying the regulation of MTUS1 are unclear. In the present study, we reported that miR-19a and miR-19b (miR-19a/b) promote proliferation and migration of lung cancer cells by targeting MTUS1. First, MTUS1 was proved to function as a tumor suppressor in lung cancer and was linked to cell proliferation and migration promotion. Second, an inverse correlation between miR-19a/b expression and MTUS1 mRNA/protein expression was noted in human lung cancer tissues. Third, MTUS1 was appraised as a direct target of miR-19a/b by bioinformatics analysis. Fourth, direct MTUS1 regulation by miR-19a/b in lung cancer cells was experimentally affirmed by cell transfection assay and luciferase reporter assay. Finally, miR-19a/b were shown to cooperatively repress MTUS1 expression and synergistically regulate MTUS1 expression to promote lung cancer cell proliferation and migration. In conclusion, our findings have provided the first clues regarding the roles of miR-19a/b, which appear to function as oncomirs in lung cancer by downregulating MTUS1.

Indexed as

Cell MovementCell ProliferationGene Expression Regulation, NeoplasticA549 CellsFemaleHumansLung NeoplasmsMaleMicroRNAsRNA, NeoplasmTumor Suppressor ProteinsMicroRNAsMIRN19A microRNA, humanMTUS1 protein, humanRNA, NeoplasmTumor Suppressor Proteinslung cancermicroRNAmigrationmiR-19a/bMTUS1proliferation

Identifiers

PMID28364280
PMCPMC5445029
OpenAlexW2602656443

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.